Bioavailability and Safety of Dihydroquercetin (Review)

• DOI: 10.1007/s11094-022-02548-8
• Publication Date: 2022-02-11T05:06:04Z
• Authors: S. V. Orlova; V. V. Tatarinov; E. A. Nikitina; A. V. Sheremeta; V. A. Ivlev; V. G. Vasil’ev; K. V. Paliy; S. V. Goryainov
• Keywords: 0301 basic medicine; 03 medical and health sciences; Molecular-Biological Problems of Drug Design and Mechanism of Drug Action; 3. Good health

Dihydroquercetin (DHQ) is a bioflavonoid with high antioxidant, capillary-protective, and anti-inflammatory activity. DHQ has previously been used for treating Middle East respiratory syndrome coronavirus (MERS-CoV) infection and is currently considered a potential regulator of oxidative stress as part of COVID-19 multipurpose therapy. DHQ has a high safety profile but low bioavailability that limits its use. Innovative techniques (liposomization, crystal engineering, etc.) can be used to increase its bioavailability.